All In Biotech

Drug Trial Radar · NCT07871110

Safety, Efficacy and Pharmacokinetics of TT00420 Tablets Combined With Novel Endocrine Therapy in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)

An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Safety, Efficacy and Pharmacokinetics of TT00420 Tablets Combined With Novel Endocrine Therapy in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Progressing After Prior Treatment

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 182 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

182

Planned (sponsor's estimate)

Start

Sep 18, 2026

Primary completion

Dec 31, 2028

Study completion Jun 30, 2029

Sponsor

Sponsor type
Industry
First posted
Oct 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if tinengotinib combined with darolutamide or enzalutamide works to treat participants with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on prior androgen receptor pathway inhibitors (ARPIs). It will also learn about the safety of the combination therapy. The main questions it aims to answer are: 1. If participants with mCRPC can benefit from the combination therapy of tinengotinib plus one ARPI? 2. What medical problems do participants have when taking the combination therapy? Participants will take tinengotinib with darolutamide or enzalutamide to find the optimal dose and regimen of tinengotinib for the combination therapy in stage A. In stage B, participants will take preferred combination regimen of tinengotinib plus darolutamide/enzalutamide identified in stage A. In stage C, researchers will compare selected combination therapy versus standard treatment and/or monotherapy to see if the combination therapy works better.

Conditions

  • Prostate Cancer (CRPC)

Interventions

  • tinengotinib 10 mg QD plus darolutamideDrug

    Participants will receive tinengotinib 10 mg once daily with darolutamide in 21-day cycles per protocol defined schedule.

  • tinengotinib 10 mg QD (2-week on / 1-week off) plus darolutamideDrug

    Participants will receive tinengotinib 10 mg once daily (2-week on / 1-week off) with darolutamide in 21-day cycles per protocol defined schedule.

  • tinengotinib 10 mg QD plus enzalutamideDrug

    Participants will receive tinengotinib 10 mg once daily with enzalutamide in 21-day cycles per protocol defined schedule.

  • preferred combination regimen of tinengotinib plus one ARPIDrug

    Participants will receive preferred combination regimen of tinengotinib at optimized dose plus one ARPI in 21-day cycles per protocol defined schedule.

  • selected combination regimen of tinengotinib plus one ARPIDrug

    Participants will receive selected combination regimen of tinengotinib at optimized dose plus one ARPI in 21-day cycles per protocol defined schedule.

  • Darolutamide 600 mg twice dailyDrug

    Participants will receive darolutamide 600 mg twice daily in 21-day cycles per protocol defined schedule.

  • Enzalutamide 160mg daily (oral)Drug

    Participants will receive enzalutamide 160mg daily (oral) in 21-day cycles per protocol defined schedule.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Stage A: safety evaluation parametersTime frame: From signing of the informed consent until 28 days after the last dose or the end of the study (whichever occurs first), an average of 1 year.
  2. Stage B: 6-month PFS rate (6mo-PFS)Time frame: From first study drug administration to the end of treatment, an average of 1 year.
  3. Stage C: Radiographic progression-free survival (rPFS)Time frame: From first study drug administration to the end of treatment, an average of 1 year.

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University Third Hospital

    Beijing, China · Not yet recruiting

  • Chongqing University Cancer Hospital

    Chongqing, China · Not yet recruiting

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, China · Not yet recruiting

  • The First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian, China · Not yet recruiting

  • Nanfang Hospital, Southern Medical University

    Guangzhou, Guangdong, China · Not yet recruiting

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China · Not yet recruiting

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Not yet recruiting

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, China · Not yet recruiting

  • Affiliated Drum Tower Hospital, Medical School of Nanjing University

    Nanjing, Jiangsu, China · Recruiting

  • Nantong Cancer Hospital

    Nantong, Jiangsu, China · Not yet recruiting

  • Shandong Cancer Hospital and Institute, Shandong First Medical University

    Jinan, Shandong, China · Not yet recruiting

  • Sichuan Cancer Hospital

    Chengdu, Sichuan, China · Not yet recruiting

  • Zhejiang Provincial People's Hospital

    Hangzhou, Zhejiang, China · Not yet recruiting

  • The First Hospital of Jiaxing

    Jiaxing, Zhejiang, China · Not yet recruiting

  • The First Affiliated Hospital of Ningbo University

    Ningbo, Zhejiang, China · Not yet recruiting

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.